The landscape of cancer diagnostics is evolving with molecular and protein biomarkers indispensable for accurate diagnosis, therapy selection, monitoring treatment response, and early detection of cancer recurrence. Kalorama Information's "The World Market for Cancer Diagnostics, 2024-2029" delivers an authoritative and comprehensive analysis of the global cancer in vitro diagnostics (IVD) market, including industry-defining trends, market sizing, and growth opportunities.
This report offers an in-depth review of the cancer IVD market, including expert insights into significant segment markets:
While focusing on these pivotal categories, the report provides limited coverage of imaging, hematology, clinical chemistry, flow cytometry, Pap smears, and traditional stains. Key developments, product launches, and regulatory announcements that shape the cancer IVD market are analyzed, along with forecasts for market growth from 2024 to 2029.
Key Highlights
Shift to Biofluid-Based Diagnostics: Although tissue-based diagnostics dominate the current market, there is growing momentum toward biofluid-based tests (e.g., blood, urine) for cancer detection and monitoring.
Market Dynamics: The forecasted growth reflects anticipated product innovations, cancer epidemiology trends, and demographic shifts, with revenue estimates based on factory-level sales to end users.
Comprehensive Insights: The report incorporates global cancer statistics, technological advancements, and competitive trends to provide a nuanced view of the market's evolution.
Report Structure
1. Executive Summary - A concise overview of key findings and market scope.
2. Introduction and Overview - Background and terminology for context.
3. Market Trends - Emerging trends shaping the cancer diagnostics industry.
4. Market Revenues and Forecasts - Detailed revenue projections by segment through 2029.
5. Competitive Analysis - Analysis of key market players and competitive developments.
6. Corporate Profiles - Profiles of leading companies in the cancer diagnostics space.
Table of Contents
Chapter 1: Executive Summary
Overview
Scope and Methodology
Market Overview and Analysis
Figure 1-1: Global Cancer IVD Market Size and Forecast, 2024-2029 ($ million)
Chapter 2: Introduction, Background, and Overview
Global Cancer Burden
Figure 2-1: Incidence of Cancer, by Type, 2020 (Bladder, Breast, Cervix Uteri, Colorectum, Liver, Lung, Oesophagus, Prostate, Stomach, Thyroid)
Figure 2-2: Global Distribution of Cancer Incidence, Estimated Number of New Cases, by Type, 2020 (%) (Breast, Cervix Uteri, Colorectum, Liver, Lung, Prostate, Stomach, Thyroid, Other Cancers)
Introduction to Cancer
Biochemistry of Cancer Cells
Causes of Cancer Growth May Shed Light on Treatment
Environmental Factors, DNA, RNA
Table 2-1: Virus Association with Human Cancer
Cellular Oncogenes
Tumor Suppressor Genes
Large Range of IVDs Applied
Histology and Cytology
In Situ Hybridization (ISH)
Immunoassays
Polymerase Chain Reaction (PCR)
Companion Diagnostics
Table 2-2: FDA Approved or Cleared Companion Diagnostic (CDx) Tests and Corresponding Therapies, Oncology
Table 2-3: Selected Major Biomarkers in Oncology Personalized Medicine Tests
Predictive Biomarker Tests for Drug-Gene Match
DNA and RNA Variants
Table 2-4: Human Genome and Cancer Gene Identification
Table 2-5: Relevant DNA/RNA Variants for Top Six Cancer Types (Breast, Colon, Gastric, Liver/Biliary, Lung, Prostate)
Table 2-6: Relevant DNA/RNA Variants for Top Six Cancer Types (excl. top six) (Brain, Cervical, Esophagus, Leukemia, Lymphoma, Melanoma, Ovarian, Pancreatic, Sarcoma, Thyroid)
Diagnostics in Hereditary Cancer Diagnosis
Table 2-7: Select Innovations in Molecular Cancer Risk Detection and Prevention
Table 2-8: Selected Companies Offering LDTs for Hereditary Risk of Cancer
Cancer Markers in Widespread Usage
Cancer Treatment Approaches
Table 2-9: Characteristics of Cancer Treatment Approaches (Chemotherapy, Hormone Therapy, Precision Therapy)
What is Precision Cancer Therapy?
Table 2-10: Industry Recognized Terms for Companion Diagnostics and Personalized Medicine
Chapter 3: Market Trends
Growth in Precision Medicine, Companion Diagnostics, Related Applications
Table 3-1: Selected Molecular Companion and Complementary Assays for Cancer
Table 3-2: Selected Pharmacogenomic Biomarkers and Drugs' Labeling, FDA
Table 3-3: Selected FDA Cleared/Approved Companion Diagnostic Tests and Therapeutic Application
Pharmacodiagnostic Tests
Table 3-4: Selected Liquid Biopsy Innovations
Liquid Biopsy-based Non-Invasive Cancer Molecular Diagnostics
Table 3-8: Selected Mass Spectrometry-Based Oncology Tests
Regulatory and Reimbursement Trends
Reimbursement Breakthroughs and Challenges
Next Generation Sequencing Coverage
Companion Diagnostics Seeing Development in Regulations
Table 3-9: FDA Approved Companion Diagnostics Labeled for Identifying Patients with NSCLC whose Tumors have EGFR Exon 19 Deletions or Exon 21 (L858R) Substitution Mutations and the Associated Therapeutic Products
Figure 3-1: Growth in Precision Cancer Therapeutics by Company 2010 vs. 2022 ($ million)
Figure 3-2: Growth Trend by Company, 2010-2022 CAGR: Precision Cancer Therapeutics (%)